Reports

Ideas That Generate Results

1. Analyst View

2. Research Methodology

3. Orphan Drug - An Introduction

4. Drivers and Challenges
    4.1 Drivers
           4.1.1 Rising Healthcare Expenditure
           4.1.2 Increasing Prevalence of Chronic Diseases
           4.1.3 Shorter Development Timeline & Orphan Drug Exclusivity (ODE)
           4.1.4 Grants and Tax Credits
    4.2 Challenges
           4.2.1 High Cost of Orphan Drugs
           4.2.2 Lack of Disease History Awareness & Research Participants
           4.2.3 Increased Competition from Generics Industry

5. Global Orphan Drug Market - Overview

6. Market Segmentation
    6.1 By Type
    6.2 By Geography
    6.3 By Applications

7. Current Status of Orphan Drugs in Pipeline

8. Trends and Developments
     8.1 Rise in Number of Orphan Drugs for Oncology
     8.2 Gene Therapy- Gaining Popularity for Rare Conditions

9. Mergers and Acquisitions

10. Regulatory Scenario
      10.1 US
      10.2 EU
      10.3 Japan
      10.4 India
      10.5 China

11. Competitive Landscape

12. Key Player Analysis
      12.1 Novartis
      12.2 F. Hoffmann-La Roche AG
      12.3 Celgene Corporation
      12.4 Pfizer Inc.
      12.5 Sanofi
      12.6 Bristol-Myers Squibb
      12.7 Johnson & Johnson
      12.8 Merck & Co., Inc.
      12.9 Boehringer Ingelheim GmbH
      12.10 AbbVie

13. Opportunities & Recommendations
       13.1 Opportunities
       13.2 Recommendations